Arrowhead Pharmaceuticals Chief Medical Officer Javier San Martin Sells 36% Of Holding
Arrowhead Pharmaceuticals Chief Medical Officer Javier San Martin Sells 36% Of Holding
We wouldn't blame Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) shareholders if they were a little worried about the fact that Javier San Martin, the Chief Medical Officer recently netted about US$567k selling shares at an average price of US$28.80. That's a big disposal, and it decreased their holding size by 36%, which is notable but not too bad.
如果Arrowhead Pharmicals, Inc.(納斯達克股票代碼:ARWR)的股東對首席醫療官哈維爾·聖馬丁最近淨賺約56.7萬美元以28.80美元的平均價格出售股票,我們就不會責怪他們。這是一個很大的處置,它使他們的持股規模減少了36%,這值得注意但還不算太糟糕。
See our latest analysis for Arrowhead Pharmaceuticals
查看我們對 Arrowhead Pharmicals 的最新分析
The Last 12 Months Of Insider Transactions At Arrowhead Pharmaceuticals
Arrowhead Pharmicals 過去12個月的內幕交易
Notably, that recent sale by Javier San Martin is the biggest insider sale of Arrowhead Pharmaceuticals shares that we've seen in the last year. That means that an insider was selling shares at around the current price of US$28.96. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign.
值得注意的是,哈維爾·聖馬丁最近的出售是我們去年見過的最大規模的Arrowhead Pharmicals股票內幕出售。這意味着一位內部人士正在以目前的28.96美元左右的價格出售股票。雖然我們通常不喜歡看到內幕拋售,但更令人擔憂的是銷售是否以較低的價格進行。我們注意到,此次銷售的價格約爲當前價格,因此這並不是一個主要問題,儘管這並不是一個好兆頭。
In the last year Arrowhead Pharmaceuticals insiders didn't buy any company stock. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
去年,Arrowhead Pharmicals內部人士沒有購買任何公司股票。下圖顯示了去年的內幕交易(公司和個人)。如果您想確切地知道誰售出、售價多少、何時出售,只需點擊下圖即可!
![insider-trading-volume](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231123/0-c3197c9787e5d97071efd64205da36d4-0-ecd8e1333fe7801a4a990b4eb12ab4de.png/big)
If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: insiders have been buying them).
如果你喜歡買內部人士買入而不是賣出的股票,那麼你可能會喜歡這份免費的公司名單。(提示:業內人士一直在購買它們)。
Insider Ownership Of Arrowhead Pharmaceuticals
箭頭製藥的內部所有權
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. I reckon it's a good sign if insiders own a significant number of shares in the company. Arrowhead Pharmaceuticals insiders own about US$92m worth of shares. That equates to 3.0% of the company. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
查看公司的內部人持股總額可以幫助您了解他們是否與普通股股東保持良好關係。我認爲,如果內部人士擁有該公司的大量股份,那將是一個好兆頭。Arrowhead Pharmicals內部人士擁有價值約9200萬美元的股票。這相當於該公司的3.0%。當然,我們在其他地方看到了更高的內幕所有權水平,但這些持股足以表明內部人士與其他股東保持一致。
What Might The Insider Transactions At Arrowhead Pharmaceuticals Tell Us?
Arrowhead Pharmicals的內幕交易可能告訴我們什麼?
Insiders haven't bought Arrowhead Pharmaceuticals stock in the last three months, but there was some selling. Looking to the last twelve months, our data doesn't show any insider buying. Insider ownership isn't particularly high, so this analysis makes us cautious about the company. So we'd only buy after careful consideration. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Arrowhead Pharmaceuticals. While conducting our analysis, we found that Arrowhead Pharmaceuticals has 1 warning sign and it would be unwise to ignore this.
在過去的三個月中,業內人士沒有買入Arrowhead Pharmicals的股票,但有一些人拋售。展望過去的十二個月,我們的數據並未顯示任何內幕買盤。內部所有權並不是特別高,因此這種分析使我們對公司持謹慎態度。因此,我們只有在仔細考慮後才會購買。除了了解正在進行的內幕交易外,確定Arrowhead Pharmicals面臨的風險也是有益的。在進行分析時,我們發現Arrowhead Pharmicals有1個警告信號,忽視這一點是不明智的。
But note: Arrowhead Pharmaceuticals may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
但請注意:Arrowhead Pharmicals可能不是最值得買入的股票。因此,來看看這份免費列出的投資回報率高、債務低的有趣公司的名單。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。